Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge.

Abstract:

:Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants. However, diagnostic dilemmas may arise in daily practice due to overlap of BL with subsets of other aggressive, mature B-cell lymphomas such as diffuse large B-cell lymphomas (DLBCL). Recently, two gene expression studies have described a distinct molecular profile for BL, but also showed the persistence of some cases intermediate between BL and DLBCL. An alternative approach to define BL is to consider (cyto)genetic data, in particular chromosomal abnormalities other than the t(8;14) or its variants. In this review the 'Mitelman Database of Chromosome Aberrations in Cancer,' harboring the majority of all published neoplasia-related karyotypes, was explored to define a cytogenetic profile of 'true' BL. This core subset of BL showed a very low complexity of chromosomal abnormalities with 40% of the cases having the IG-MYC fusion as the sole abnormality. In the remaining cases, additional recurrent but partially exclusive abnormalities included gains at chromosomes 1q, 7 and 12, and losses of 6q, 13q32-34 and 17p. Within the core subset, no differences were found between pediatric and adult patients. In addition, the genetic profile of the core subset was significantly different from BL with an 8q24 breakpoint not affecting one of the three immunoglobulin loci, BL with a translocation involving 18q21/BCL2, 3q27/BCL6 or 11q13/BCL1, additionally to a breakpoint at 8q24/MYC, and from other morphological types of lymphomas with an 8q24/MYC breakpoint. These groups showed a higher cytogenetic complexity than the core subset of BL. BL without a detectable 8q24/MYC breakpoint might be heterogeneous and deserves further studies. We suggest that, concordant with the WHO classification to be published in 2008, the diagnosis of BL should be restricted to cases with expression of CD10 and BCL6, absence or very weak expression of BCL2 protein, a homogeneously very high proliferation index and a proven IG-MYC translocation without evidence of a chromosomal translocation typical for other lymphoma entities. In addition, a high number of nonspecific cytogenetic abnormalities should suggest need for a critical review of the diagnosis of BL.

journal_name

Leukemia

journal_title

Leukemia

authors

Boerma EG,Siebert R,Kluin PM,Baudis M

doi

10.1038/leu.2008.281

subject

Has Abstract

pub_date

2009-02-01 00:00:00

pages

225-34

issue

2

eissn

0887-6924

issn

1476-5551

pii

leu2008281

journal_volume

23

pub_type

历史文章,杂志文章,评审

相关文献

LEUKEMIA文献大全
  • Tissue factor and plasminogen activator inhibitor expression in the differentiation of myeloid leukemic cells.

    abstract::Disturbances in the regulation of the balance between the fibrinolytic and procoagulant properties of leukemic cells may contribute to the coagulopathy of acute leukemia. The coagulant response to a number of stimuli is regulated by the expression of tissue factor, but the role of the plasminogen activator inhibitors,...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dickinson JL,Antalis TM

    更新日期:1993-06-01 00:00:00

  • Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.

    abstract::Epigenetic deregulation is involved in acute myeloid leukemia (AML) pathogenesis and epigenetic targeting drugs are in clinical trial. Since the first results with histone-deacetylase inhibitors in AML are controversial, novel single and combined treatments need to be explored. It is tempting to combine chromatin-targ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.271

    authors: Chaib H,Nebbioso A,Prebet T,Castellano R,Garbit S,Restouin A,Vey N,Altucci L,Collette Y

    更新日期:2012-04-01 00:00:00

  • DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.

    abstract::Dipeptidylpeptidase 4 (DPP4/CD26) enzymatically cleaves select penultimate amino acids of proteins, including colony-stimulating factors (CSFs), and has been implicated in cellular regulation. To better understand the role of DPP4 regulation of hematopoiesis, we analyzed the activity of DPP4 on the surface of immature...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.98

    authors: O'Leary HA,Capitano M,Cooper S,Mantel C,Boswell HS,Kapur R,Ramdas B,Chan R,Deng L,Qu CK,Broxmeyer HE

    更新日期:2017-11-01 00:00:00

  • Treatment of resistant disease.

    abstract::Resistant AML encompasses two groups of patients: those with refractory leukemia and those whose leukemia has relapsed. Refractory leukemia is disease that does not respond to initial induction chemotherapy with cytarabine and an anthracycline. Patients with refractory leukemia are likely to have disease with adverse ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Schiller GJ

    更新日期:1998-09-01 00:00:00

  • Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations.

    abstract::Molecular analysis of T cell receptor (TCR) genes is frequently used to prove or exclude clonality and thereby support the diagnosis of suspect T cell proliferations. PCR techniques are more and more being used for molecular clonality studies. The main disadvantage of the PCR-based detection of clonal TCR gene rearran...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400887

    authors: Langerak AW,Szczepański T,van der Burg M,Wolvers-Tettero IL,van Dongen JJ

    更新日期:1997-12-01 00:00:00

  • All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenitors in vitro.

    abstract::All-trans retinoic acid (ATRA) has recently been shown to synergize with the inhibitory effect of interferon alpha (IFN alpha) on the growth of malignant cells isolated from solid tumors. We investigated whether ATRA could potentiate the inhibitory effects of IFN alpha on the proliferation of leukemic progenitors in c...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400611

    authors: Mahon FX,Chahine H,Barbot C,Pigeonnier V,Jazwiec B,Reiffers J,Ripoche J

    更新日期:1997-05-01 00:00:00

  • bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis.

    abstract::We looked for bcl-2 protein expression by immunocytochemistry on bone marrow slides from 51 cases of myelodysplastic syndrome (MDS), of whom 25 received some form of chemotherapy. Forty-six of them had at least 20% bcl-2 positive blasts and the median percentage of positive blasts was 80%, whereas myeloid cells beyond...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lepelley P,Soenen V,Preudhomme C,Merlat A,Cosson A,Fenaux P

    更新日期:1995-04-01 00:00:00

  • Correction: Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.

    abstract::An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title:Leukemia

    pub_type: 已发布勘误

    doi:10.1038/s41375-020-0821-1

    authors: Thastrup M,Marquart HV,Levinsen M,Grell K,Abrahamsson J,Albertsen BK,Frandsen TL,Harila-Saari A,Lähteenmäki PM,Niinimäki R,Pronk CJ,Ulvmoen A,Vaitkevičienė G,Taskinen M,Schmiegelow K,Nordic Society of Pediatric Hematology a

    更新日期:2020-10-01 00:00:00

  • MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias.

    abstract::Retroviral insertional mutagenesis in BXH2 mice commonly induces myeloid leukemias. One of the most frequently involved genes in experimental studies is Meis 1. In contrast to other genes in murine models, Meis 1 has not been affected by recurrent chromosomal translocations or point mutations in human leukemias. We fo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403377

    authors: Lasa A,Carnicer MJ,Aventín A,Estivill C,Brunet S,Sierra J,Nomdedéu JF

    更新日期:2004-07-01 00:00:00

  • Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML.

    abstract::The transcription factor CCAAT enhancer-binding protein alpha (C/EBPalpha) has an important role in granulopoiesis. The tumor suppressor function of C/EBPalpha is shown by the findings that loss of expression or function of C/EBPalpha in leukemic blasts contributes to a block in myeloid cell differentiation and to leu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.37

    authors: Pulikkan JA,Dengler V,Peer Zada AA,Kawasaki A,Geletu M,Pasalic Z,Bohlander SK,Ryo A,Tenen DG,Behre G

    更新日期:2010-05-01 00:00:00

  • Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms.

    abstract::Tumorigenesis can be considered as pathologically misappropriated tissue regeneration. In this review we will address some unresolved issues that support this concept. First, we will address the issue of the identity of cancer-initiating cells and the presence of cancer stem cells in growing tumors. We will also ask a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-018-0294-7

    authors: Ratajczak MZ,Bujko K,Mack A,Kucia M,Ratajczak J

    更新日期:2018-12-01 00:00:00

  • Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.

    abstract::Activation of the MEK/ERK/MAP kinase signaling pathway promotes the proliferation and survival of hematopoietic cells. The kinases MEK-1, MEK-2, ERK-1/MAPK and ERK-2/MAPK are activated by phosphorylation at specific sites, and these events can be monitored using phospho-specific antibodies. In this report we examined ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402400

    authors: Miranda MB,McGuire TF,Johnson DE

    更新日期:2002-04-01 00:00:00

  • Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.

    abstract::Previous studies in pediatric patients with acute myelogenous leukemia (AML) have suggested that 2-chlorodeoxyadenosine (2CdA) is an effective therapeutic agent. Santana et al (J Clin Oncol 1992; 10: 364-370) reported a CR rate of 8/17 (95% Cl 23-72%) in children with relapsed AML and a median first CR of 21 months. T...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kornblau SM,Gandhi V,Andreeff HM,Beran M,Kantarjian HM,Koller CA,O'Brien S,Plunkett W,Estey E

    更新日期:1996-10-01 00:00:00

  • Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.

    abstract::Novel approaches have been designed to treat leukemia based on our understanding of the genetic and biochemical lesions present in different malignancies. This meeting report summarizes some of the recent advances in leukemia treatment. Based on the discoveries of cellular oncogenes, chromosomal translocations, monocl...

    journal_title:Leukemia

    pub_type:

    doi:10.1038/sj.leu.2403156

    authors: Larson RA,Daley GQ,Schiffer CA,Porcu P,Pui CH,Marie JP,Steelman LS,Bertrand FE,McCubrey JA

    更新日期:2003-12-01 00:00:00

  • A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

    abstract::We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen. Fifteen patients with advanced leukemia (12 with acute myeloid leukemia, 2 with acute lymphoblastic leukemia, 1 with biphenotypic) and...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.132

    authors: Pratz KW,Cho E,Levis MJ,Karp JE,Gore SD,McDevitt M,Stine A,Zhao M,Baker SD,Carducci MA,Wright JJ,Rudek MA,Smith BD

    更新日期:2010-08-01 00:00:00

  • Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

    abstract::In acute myeloid leukemia (AML), assessment of minimal residual disease (MRD) by flow cytometry (flow MRD) after induction and consolidation therapy has been shown to provide independent prognostic information. However, data on the value of earlier flow MRD assessment are lacking. Therefore, the value of flow MRD dete...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.186

    authors: Köhnke T,Sauter D,Ringel K,Hoster E,Laubender RP,Hubmann M,Bohlander SK,Kakadia PM,Schneider S,Dufour A,Sauerland MC,Berdel WE,Büchner T,Wörmann B,Braess J,Hiddemann W,Spiekermann K,Subklewe M

    更新日期:2015-02-01 00:00:00

  • JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation.

    abstract::The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.114

    authors: Zhan H,Ma Y,Lin CH,Kaushansky K

    更新日期:2016-12-01 00:00:00

  • Stromal cell-mediated transcriptional regulation of the CD13/aminopeptidase N gene in leukemic cells.

    abstract::CD13/aminopeptidase N (APN) is a cell surface metallopeptidase expressed by normal and leukemic myeloid cells, and by lymphoblasts in 5-10% of acute lymphoid leukemia (ALL) cases, previously classified as 'biphenotypic' or 'mixed-lineage' leukemias. In fresh cells from two early B-lineage, t(9;22)-positive, ALL cases ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Saito M,Kumagai M,Okazaki T,Nakazawa S,Shapiro LH,Look AT,Campana D

    更新日期:1995-09-01 00:00:00

  • Update of St Jude Study XI for childhood acute lymphoblastic leukemia.

    abstract::We treated 358 children with non-B-cell acute lymphoblastic leukemia with intensive multiagent chemotherapy (St. Jude Study XI) in a risk-directed study which used very intensive induction and consolidation therapy followed by continuation treatment comprised of rotating drug pairs given for the entire duration of the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Rivera GK,Pui CH,Hancock ML,Mahmoud H,Santana V,Sandlund JT,Hurwitz C,Ribeiro R,Furman W,Crist WM

    更新日期:1992-01-01 00:00:00

  • Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.

    abstract::Some anaplastic large cell lymphomas (ALCLs) carry a specific chromosomal translocation, t(2;5)(p23;q35). Recently, we found a novel hyperphosphorylated 80-kDa protein tyrosine kinase, p80, in ALCLs with t(2;5). Subsequent cDNA cloning revealed p80 to be a fusion protein of two genes, the novel tyrosine kinase gene an...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Shiota M,Mori S

    更新日期:1997-04-01 00:00:00

  • Immunophenotypic features and configuration of immunoglobulin genes in hairy cell leukemia-Japanese variant.

    abstract::Immunophenotypes and Ig gene rearrangements were investigated in 12 patients with a variant form of hairy cell leukemia (HCL) termed HCL-Japanese variant (HCL-J), and in an HCL-J-derived cell line. The leukemic cells of HCL-J characteristically showed the phenotype of CD20+, CD5-, CD10-, CD11c+, CD22+, CD24- and CD25-...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Yamaguchi M,Machii T,Shibayama H,Tokumine Y,Hara J,Yutsudo M,Yamada O,Klobeck HG,Kitani T

    更新日期:1996-08-01 00:00:00

  • Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

    abstract::P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates other cellular processes. Here, we describe a role of p38α/β as a regulator of acute lymphoblastic leukemia (ALL) proliferation and survival in experimental ALL m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.153

    authors: Alsadeq A,Strube S,Krause S,Carlet M,Jeremias I,Vokuhl C,Loges S,Aguirre-Ghiso JA,Trauzold A,Cario G,Stanulla M,Schrappe M,Schewe DM

    更新日期:2015-12-01 00:00:00

  • CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease.

    abstract::CD44 variant isoforms (CD44v) have been shown to be important factors in adverse prognosis in hematological malignancies. To investigate whether CD44 expression is associated with malignant transformation in multiple myeloma, RNA and protein expression of CD44 standard (CD44s) and CD44v4, v6, v9, v10 containing isofor...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401179

    authors: van Driel M,Günthert U,Stauder R,Joling P,Lokhorst HM,Bloem AC

    更新日期:1998-11-01 00:00:00

  • Schedule-dependent efficacy of idarubicin (Ida) and doxorubicin (Dox).

    abstract::Schedule dependency of idarubicin (Ida) and doxorubicin (Dox) toxicity was investigated in vitro using the K562 human leukemia cell line. For Dox, repeated exposure to the IC30 (d x 3) resulted in comparable survival as single exposure to the total accumulative dose (20%). For Ida, repeated exposure to the IC30 (d x 3...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Minderman H,Buscaglia MD,Rustum YM

    更新日期:1994-08-01 00:00:00

  • CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

    abstract::The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite tar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0684-5

    authors: Kinstrie R,Horne GA,Morrison H,Irvine D,Munje C,Castañeda EG,Moka HA,Dunn K,Cassels JE,Parry N,Clarke CJ,Scott MT,Clark RE,Holyoake TL,Wheadon H,Copland M

    更新日期:2020-06-01 00:00:00

  • Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes.

    abstract::B-cell chronic lymphocytic leukaemia (B-CLL) is a slowly progressing malignancy of CD5(+) B cells, for which at present no curative treatment is available. In our current study, we apply a novel bridging reagent to redirect cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) to target B-CLL. A streptavidin-fu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404185

    authors: Mous R,Savage P,Remmerswaal EB,van Lier RA,Eldering E,van Oers MH

    更新日期:2006-06-01 00:00:00

  • Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes.

    abstract::Translocations involving the immunoglobulin loci are recurring events of B cell oncogenesis. The majority of translocations involve the immunoglobulin heavy chain (IGH) locus, while a minor part involves the immunoglobulin light chain loci consisting of the kappa light chain (IGK) located at 2p11.2 and the lambda ligh...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402648

    authors: Poulsen TS,Silahtaroglu AN,Gisselø CG,Tommerup N,Johnsen HE

    更新日期:2002-10-01 00:00:00

  • The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype.

    abstract::To examine whether the percentage of myeloperoxidase (MPO)-positive blast cells is useful as a prognostic factor for acute myeloid leukemia (AML), cytochemical analysis of MPO was performed in 491 patients who were registered to the Japan Adult Leukemia Study Group-AML92 study. Patients were divided into two using the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403010

    authors: Matsuo T,Kuriyama K,Miyazaki Y,Yoshida S,Tomonaga M,Emi N,Kobayashi T,Miyawaki S,Matsushima T,Shinagawa K,Honda S,Ohno R,Japan Adult Leukemia Study Group.

    更新日期:2003-08-01 00:00:00

  • Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.

    abstract::Chimeric antigen receptor (CAR)-T-cell is a safe and effective therapy of B-cell cancers but it is unknown if this is so in persons with prior hepatitis B virus (HBV) infection. We studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 2...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0936-4

    authors: Wang Y,Liu Y,Tan X,Pan B,Ge J,Qi K,Cheng H,Cao J,Shi M,Yan Z,Qiao J,Jing G,Wang X,Sang W,Xia R,Zhang X,Li Z,Gale RP,Zheng J,Zhu F,Xu K

    更新日期:2020-10-01 00:00:00

  • Translocation t(6;9)(p23;q34) in acute myeloid leukemia without myelodysplasia or basophilia: two cases and a review of the literature.

    abstract::The clinical, hematological, and cytogenetic data from two young adults with acute myeloid leukemia (AML) FAB type M1 is described. At diagnosis, cytogenetic investigation revealed the presence of the translocation t(6;9)(p23;q34). Bone marrow basophilia was not detected in either patient nor was there any evidence of...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Lillington DM,MacCallum PK,Lister TA,Gibbons B

    更新日期:1993-04-01 00:00:00